ראיון מקיף על הקורונה עם רופא מומחה למחלות ריאה בהודו: "להערכתי אנחנו לקראת סוף המגפה."

Small RCT with 72 low-risk patients in Thailand, showing improved recovery with ivermectin, without statistical significance. All patients recovered and there

RCT 99 ivermectin and 103 control low risk patients in China, up to 7 days from symptom onset, showing statistically significant improvement in recovery

RCT 490 hospitalized patients in Malaysia, showing no significant differences.

Small RCT with 61 patients in Nigeria, all patients treated with ivermectin, zinc, and vitamin C, showing no significant improvements in recovery

Early terminated 89 patient RCT with 29 high dose and 32 very high dose ivermectin patients

Review of sample size calculations in ivermectin RCTs, showing that existing RCTs are very underpowered.

RCT with 501 relatively low-risk outpatients in Argentina showing hospitalization OR 0.65 [0.32-1.31]. With only 7% hospitalization, this trial is underpowered

Proof of concept RCT with 30 ivermectin patients and 15 control patients

RCT 114 patients in Egypt, 57 treated with ivermectin mucoadhesive nanosuspension intranasal spray

RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance

RCT 100 outpatients in Pakistan, 50 treated with ivermectin, showing faster recovery with ivermectin

Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases

Cluster RCT outpatients in Argentina showing significantly faster recovery with ivermectin

Phase 2 results from a multicenter RCT of hospitalized patients in Bulgaria showing faster viral clearance

Very small RCT with 4 control patients and 28 ivermectin patients split across 3 different dosage levels, showing lower (non-statistically significant)

RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermectin not showing significant differences.